Company profile
Accustem Sciences Inc. CIK 1850767
Ticker
ACUT (OTC)
Industry
Pharmaceutical Preparations
Headquarters
New York, NY 10001
Fiscal year end
2025 (FY)
Key Financials
Revenue
—
Net income
-$1.76M
Total assets
$1.55M
Total liabilities
$4.95M
Stockholders' equity
-$3.40M
Cash & equivalents
—
Operating income
-$1.76M
Operating cash flow
-$850.4K
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-04-14. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
319.5%
Equity / assets
-219.5%
CapEx / revenue
—
Operating cash flow / net income
0.48×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
—
-$1.76M
$1.55M
$4.95M
-$3.40M
2024
—
-$1.51M
$50.9K
$3.36M
-$3.31M
2023
—
-$2.05M
$133.9K
$2.25M
-$2.11M
2022
—
-$3.75M
$939.7K
$1.08M
-$139.6K
2021
—
-$670.6K
$1.35M
$702.7K
$650.7K
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-14
Financials filed via
Form 10-K
filed 2026-04-14
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
New York, NY 10001
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:46 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.